Adjuvant IMRT With Concommitant Raltitrexed Chemotherapy for Locally Advanced Gastric Cancer After D0/D1 Radical Resection
Primary Purpose
Gastric Cancer
Status
Unknown status
Phase
Phase 2
Locations
China
Study Type
Interventional
Intervention
Raltitrexed
postoperative radiotherapy
Sponsored by
About this trial
This is an interventional treatment trial for Gastric Cancer focused on measuring Raltitrexed, IMRT
Eligibility Criteria
Inclusion Criteria:
- Informed consent signed.;
- Age: 18-70 years old, sex is not restricted;
- Pathologically diagnosed as gastric adenocarcinoma or gastroesophageal junction adenocarcinoma; did not receive neoadjuvant chemotherapy or radiotherapy before surgery;received the 2-3 cycles of chemotherapy of FOLFOX regimens or 1-2 cycles of XeLOX or SOX regimens after operation;
- Received D0 or D1 operation, no tumor residual (R0);
- Postoperative pathological stage of pT3N0, pT4N0 or any T, N1-2, without distant metastatic disease;
- ECOG 0-2;
- Normal blood analysis: WBC≥3.5 X 109/L, GRAN≥2.0 X 109/L = 2, Hb≥90g/L, PLT≥100 X 109/L;
- Liver function: ALT or AST is less than or equal to 2.5 times of the normal high value (ULN); bilirubin is less than 1.5*ULN, serum APK is less than 2.5 * ULN;
- Renal function: serum creatinine is less than 1.5 * ULN, and creatinine clearance rate is more than 60ml/min;
- No previous chemotherapy or radiation therapy history;
- No organ transplant history;
- Urine pregnancy test results are negative for women of childbearing age in the first 7 days and not in lactation before treatment;
- Men and women of childbearing age agreed to adopt reliable methods of contraception for 30 days before , during and after the course of the study
Exclusion Criteria:
- Received D2 radical operation;
- Tumor residual (R1/R2);
- There was found evidence of distant metastasis (M1) or suspicious metastasis after examination;
- Other cancer history, except skin basal cell carcinoma or cervix in-situ carcinoma;
- Previously received chemotherapy or other systemic anticancer therapy, including cytotoxic drugs, targeted drugs; or had received abdominal radiotherapy;
- Anticipate other clinical trials in four weeks before enrollment.
- Severe complication, such as acute myocardial infarction in 6 months, uncontrolled diabetes, severe cardiac arrhythmia, etc.
- Drug abuse history or alcohol addiction;
- Active infection existed.
- with severe malnutrition or severe anemia;
- Human immunodeficiency virus (HIV) infection;
- Pregnancy (confirmed by serum or urine beta -HCG test) or during lactation;
- Can not tolerate this study or may be allergic to the drug used in this study;
- Persons who have no or restricted capacity for civil conduct; or have mental illness, whom the researchers believe can not fully understand the possible complications of this study.
Sites / Locations
- Zhongnan Hopital of Wuhan UniversityRecruiting
Arms of the Study
Arm 1
Arm Type
Experimental
Arm Label
postoperative CRT
Arm Description
postoperative CRT: Treatment including postoperative radiotherapy (IMRT) with concurrent chemotherapy of Raltitrexed. Radiotherapy will be delivered to a planning target volume with a dose of 45-50.4Gy (1.8-2.0Gy daily) using with Intensity-Modulated Radiotherapy technique. During the radiation treatment, concurrent chemotherapy will be delivered (Raltitrexed, intravenous infusion, 3 mg/m2, on w1 and w4).
Outcomes
Primary Outcome Measures
The ratio of patients occured Grade 3 or higher adverse events
Secondary Outcome Measures
2-year local-regionally recurrence rate
The probability of locally and/or regionally recurrence at 2 year after CRT on imaging or pathological examination.
3-year local-regionally recurrence rate
The probability of locally and/or regionally recurrence at 3 year after CRT on imaging or pathological examination.
2-year disease-free survival probability
The probability of staying free from recurrence at 2 year after CRT on imaging or pathological examination.
3-year disease-free survival probability
The probability of staying free from recurrence at 3 year after CRT on imaging or pathological examination.
2-year overall survival probability
The probability of staying alive at 2 year after CRT.
3-year overall survival probability
The probability of staying alive at 3 year after CRT.
Full Information
1. Study Identification
Unique Protocol Identification Number
NCT03392103
Brief Title
Adjuvant IMRT With Concommitant Raltitrexed Chemotherapy for Locally Advanced Gastric Cancer After D0/D1 Radical Resection
Official Title
Adjuvant IMRT With Concommitant Raltitrexed Chemotherapy for Locally Advanced Gastric Cancer After D0/D1 Radical Resection
Study Type
Interventional
2. Study Status
Record Verification Date
December 2017
Overall Recruitment Status
Unknown status
Study Start Date
January 2017 (undefined)
Primary Completion Date
December 2019 (Anticipated)
Study Completion Date
December 2019 (Anticipated)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Zhongnan Hospital
4. Oversight
Data Monitoring Committee
Yes
5. Study Description
Brief Summary
The purpose of this study is to determine whether raltitrexed concurrent with IMRT is safe, tolerable and effective in the treatment for patients with local-advanced gastric cancer after D0/D1 radical resection.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Gastric Cancer
Keywords
Raltitrexed, IMRT
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 2
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
48 (Anticipated)
8. Arms, Groups, and Interventions
Arm Title
postoperative CRT
Arm Type
Experimental
Arm Description
postoperative CRT: Treatment including postoperative radiotherapy (IMRT) with concurrent chemotherapy of Raltitrexed. Radiotherapy will be delivered to a planning target volume with a dose of 45-50.4Gy (1.8-2.0Gy daily) using with Intensity-Modulated Radiotherapy technique. During the radiation treatment, concurrent chemotherapy will be delivered (Raltitrexed, intravenous infusion, 3 mg/m2, on w1 and w4).
Intervention Type
Drug
Intervention Name(s)
Raltitrexed
Other Intervention Name(s)
Raltitrexed Injectable Solution
Intervention Description
concurrent chemotherapy
Intervention Type
Radiation
Intervention Name(s)
postoperative radiotherapy
Other Intervention Name(s)
adjuvant radiotherapy
Intervention Description
concurrent postoperative radiation therapy
Primary Outcome Measure Information:
Title
The ratio of patients occured Grade 3 or higher adverse events
Time Frame
From the first day of the concurrent chemoradiotherapy (CRT) to the 180th day after CRT.
Secondary Outcome Measure Information:
Title
2-year local-regionally recurrence rate
Description
The probability of locally and/or regionally recurrence at 2 year after CRT on imaging or pathological examination.
Time Frame
2 year
Title
3-year local-regionally recurrence rate
Description
The probability of locally and/or regionally recurrence at 3 year after CRT on imaging or pathological examination.
Time Frame
3 year
Title
2-year disease-free survival probability
Description
The probability of staying free from recurrence at 2 year after CRT on imaging or pathological examination.
Time Frame
2 year
Title
3-year disease-free survival probability
Description
The probability of staying free from recurrence at 3 year after CRT on imaging or pathological examination.
Time Frame
3 year
Title
2-year overall survival probability
Description
The probability of staying alive at 2 year after CRT.
Time Frame
2 year
Title
3-year overall survival probability
Description
The probability of staying alive at 3 year after CRT.
Time Frame
3 year
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
70 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Informed consent signed.;
Age: 18-70 years old, sex is not restricted;
Pathologically diagnosed as gastric adenocarcinoma or gastroesophageal junction adenocarcinoma; did not receive neoadjuvant chemotherapy or radiotherapy before surgery;received the 2-3 cycles of chemotherapy of FOLFOX regimens or 1-2 cycles of XeLOX or SOX regimens after operation;
Received D0 or D1 operation, no tumor residual (R0);
Postoperative pathological stage of pT3N0, pT4N0 or any T, N1-2, without distant metastatic disease;
ECOG 0-2;
Normal blood analysis: WBC≥3.5 X 109/L, GRAN≥2.0 X 109/L = 2, Hb≥90g/L, PLT≥100 X 109/L;
Liver function: ALT or AST is less than or equal to 2.5 times of the normal high value (ULN); bilirubin is less than 1.5*ULN, serum APK is less than 2.5 * ULN;
Renal function: serum creatinine is less than 1.5 * ULN, and creatinine clearance rate is more than 60ml/min;
No previous chemotherapy or radiation therapy history;
No organ transplant history;
Urine pregnancy test results are negative for women of childbearing age in the first 7 days and not in lactation before treatment;
Men and women of childbearing age agreed to adopt reliable methods of contraception for 30 days before , during and after the course of the study
Exclusion Criteria:
Received D2 radical operation;
Tumor residual (R1/R2);
There was found evidence of distant metastasis (M1) or suspicious metastasis after examination;
Other cancer history, except skin basal cell carcinoma or cervix in-situ carcinoma;
Previously received chemotherapy or other systemic anticancer therapy, including cytotoxic drugs, targeted drugs; or had received abdominal radiotherapy;
Anticipate other clinical trials in four weeks before enrollment.
Severe complication, such as acute myocardial infarction in 6 months, uncontrolled diabetes, severe cardiac arrhythmia, etc.
Drug abuse history or alcohol addiction;
Active infection existed.
with severe malnutrition or severe anemia;
Human immunodeficiency virus (HIV) infection;
Pregnancy (confirmed by serum or urine beta -HCG test) or during lactation;
Can not tolerate this study or may be allergic to the drug used in this study;
Persons who have no or restricted capacity for civil conduct; or have mental illness, whom the researchers believe can not fully understand the possible complications of this study.
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Jing Dai, M.D.
Phone
+86(0)2767813155
Email
daijing1116@163.com
First Name & Middle Initial & Last Name or Official Title & Degree
Ling Xai, M.D.
Phone
+86(0)2767813155
Email
22425583@qq.com
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Fuxiang Zhou, M.D.
Organizational Affiliation
Wuhan University
Official's Role
Study Chair
Facility Information:
Facility Name
Zhongnan Hopital of Wuhan University
City
Wuhan
State/Province
Hubei
ZIP/Postal Code
430071
Country
China
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Fuxiang Zhou, M.D.
Phone
+86(0)2767813155
Email
fuxiang.zhou@whu.edu.cn
First Name & Middle Initial & Last Name & Degree
Jing Dai, M.D.
Phone
+86(0)2767813155
Email
daijing1116@163.com
12. IPD Sharing Statement
Plan to Share IPD
No
Learn more about this trial
Adjuvant IMRT With Concommitant Raltitrexed Chemotherapy for Locally Advanced Gastric Cancer After D0/D1 Radical Resection
We'll reach out to this number within 24 hrs